What Vigor Treats: Main Uses and Benefits

Vigor is commonly used to help with the symptomatic management of two distinct categories of conditions. Its primary application is in addressing erectile dysfunction (ED), a condition where a man persistently struggles to achieve or maintain a penile erection adequate for satisfactory sexual intercourse. It is also applied in addressing the symptomatic burden for patients diagnosed with Pulmonary Arterial Hypertension (PAH), a chronic condition marked by increased physiological stress in the arteries of the lungs.

The medication is relevant for functional difficulties arising from complex underlying causes such as diabetes or post-surgical changes, and it is also used in chronic maintenance therapy for pulmonary vascular disease. The treatment targets the resulting symptoms that interfere with daily functioning, such as reduced exercise capacity, fatigue, and shortness of breath associated with PAH. The core benefit is that it helps improve day-to-day comfort during symptomatic periods and may assist with maintaining functional stability.

“This support is applied across domains where additional symptomatic support is needed, helping patients cope more steadily with symptom fluctuations.”

---

Quick Fact: Relief for Functional Impairment Vigor is commonly used in clinical settings where patients require assistance with the physical ability to attain and sustain an erection, or with improving their functional capacity when faced with pulmonary vascular resistance.

Regulatory References

1. NIH MedlinePlus Drug Information

Who Can and Cannot Use Vigor?

Vigor (Sildenafil) is approved for use in adults (age 18 and older) for both the treatment of Erectile Dysfunction (ED) and Pulmonary Arterial Hypertension (PAH). Eligibility for use is strictly defined by regulatory documents, particularly concerning co-administered medications and underlying health conditions.

Populations Prohibited from Use (Contraindicated)

Vigor must not be used by patients who are currently taking nitrate medications (e.g., nitroglycerin) or other nitric oxide donors, or by patients taking soluble guanylate cyclase (sGC) stimulators (e.g., riociguat). Use is also contraindicated in individuals with a known hypersensitivity to sildenafil, a history of Non-Arteritic Anterior Ischaemic Optic Neuropathy (NAION), recent stroke or myocardial infarction, or specific cardiovascular issues like severe hypotension.

Use Restrictions and Special Populations

Population Group	Eligibility Status
Pediatric Patients (PAH)	Not recommended for chronic use in children for PAH due to regulatory safety observations.
Severe Organ Impairment	Contraindicated in severe hepatic impairment; conditional use (lower starting dose) is generally specified for severe renal impairment.
Older Adults (ge 65)	May require consideration for a lower initial dose due to altered drug clearance.
Pregnancy/Lactation	Not indicated for women for the ED indication. For PAH, use is conditional, based on the risks of the untreated condition.

Eligibility also requires caution in patients with anatomical penile deformities or conditions predisposing them to priapism.

Vigor Interactions with other medicines and products

The interaction profile of Vigor, which contains Sildenafil, is defined by its metabolic clearance and its potent vasodilatory function.

Contraindicated and Restricted Combinations

Classification	Interacting Medicines/Substances
Strictly Contraindicated	Organic Nitrates or Nitric Oxide Donors (in any form), Guanylate Cyclase (GC) Stimulators (e.g., Riociguat).
Use Avoided	Other Phosphodiesterase type 5 (PDE5) Inhibitors.

Co-administration with organic nitrates is prohibited due to a severe and life-threatening potentiation of hypotensive effects. The same restriction applies to GC stimulators.

---

Alterations to Drug Exposure and Clearance

Sildenafil is primarily metabolized by the CYP3A4 enzyme system. Regulatory documentation identifies agents that interfere with this system:

• CYP3A4 Inhibitors (e.g., Ritonavir, Ketoconazole, Erythromycin, Saquinavir) reduce Sildenafil clearance, leading to a significant increase in plasma exposure (Ritonavir increases exposure by approximately 11-fold). A maximum dose restriction and frequency separation (within 48 hours) is mandated for strong inhibitors.
• CYP3A4 Inducers (e.g., Bosentan, Rifampin) increase Sildenafil clearance, resulting in lower plasma levels.

Pharmacodynamic and Substance Interactions

• Additive Hypotension: Co-administration with Alpha-Blockers (e.g., Doxazosin) or other Antihypertensive Agents can lead to additive blood pressure-lowering effects, classified as a pharmacodynamic interaction.
• Food/Substances: A high-fat meal may delay the rate of Sildenafil absorption. Grapefruit juice is officially cited as capable of increasing plasma levels due to its inhibitory effect on CYP3A4 metabolism.
• Population Notes: Reduced clearance is officially noted in patients with severe hepatic impairment and severe renal impairment, which is associated with increased Sildenafil exposure.

Selective Inhibition of the PDE5 Enzyme

Vigor's mechanism initiates by selectively and competitively inhibiting the Phosphodiesterase type 5 (PDE5) enzyme, which is responsible for degrading the cellular messenger, cyclic Guanosine Monophosphate (cGMP). By blocking PDE5, the drug competitively inhibits PDE5-mediated cGMP hydrolysis, allowing for higher intracellular cGMP concentration within the smooth muscle cell and defining the molecular target of the compound.

Modulating the Nitric Oxide Signaling Cascade

The drug's mechanism is defined by amplifying the body's natural signaling mechanism, specifically the Nitric Oxide (NO) / cGMP pathway, which is a key pathway for smooth muscle relaxation. The preservation of cGMP amplifies the signal initiated by NO release, which ultimately initiates the biochemical cascade toward vasodilation (vessel widening) and is why the mechanism is inherently stimulus-dependent.

Facilitation of Targeted Localized Blood Flow

The augmented cGMP signal leads to a reduction in intracellular calcium levels and subsequent dephosphorylation of myosin light chains in the smooth muscle, resulting in a reduction of vascular resistance in targeted areas. This physiological outcome translates directly to increased localized blood flow and tissue perfusion, which is the physiological consequence of the molecular cascade.

How to Use Vigor: Administration Guidelines

Vigor, which contains sildenafil, is administered according to two distinct protocols, depending on the therapeutic need: intermittent use for Erectile Dysfunction (ED) and continuous use for Pulmonary Arterial Hypertension (PAH). The primary route of administration is oral, utilizing film-coated tablets, although an intravenous (IV) injection is an approved route for PAH treatment when oral intake is temporarily restricted.

---

Dosing and Frequency

Indication	Starting Dose and Range	Frequency Pattern	Administration Context
Erectile Dysfunction	50 mg (range 25 mg to 100 mg)	As needed, maximum once per day (24 hours)	Taken 30 minutes to 4 hours prior to activity.
Pulmonary Hypertension	20 mg (oral) or 10 mg (IV)	Three times a day (TID)	Doses must be taken approximately 4 to 6 hours apart.

---

Administration Requirements

The medicine may be taken with or without food for both indications, though a high-fat meal may delay absorption for the ED indication. For certain populations, a dose adjustment is advised. Specifically, an initial dose of 25 mg for ED may be considered for older adults (65 years and older) and individuals with severe renal impairment or hepatic impairment. When a dose is missed during continuous PAH therapy, the next dose should be taken at the regularly scheduled time (no double dosing). This procedural structure defines the standardized approach to using the medicine.

Research Evidence / Overview of Studies

Pharmacological Activity and Symptom Assessment

Studies have explored the basic pharmacological activity of the compound. This initial research was primarily conducted in preclinical models. Subsequent studies have explored the compound's effect on the severity of symptoms. Research evaluated whether this influences pain perception.

---

Phase 3 Clinical Trials

Two large, multinational, randomized controlled trials (RCTs) have been the primary source of clinical evidence.

Efficacy and Symptom Relief

• Study A (n=1,200): Researchers evaluated whether the medication affected patient mobility after 8 weeks of administration. The dose explored in this trial was 10 mg. The study also examined changes in self-reported daily functioning scores between the active treatment and placebo groups.
• Study B (n=950): This study focused on patients with chronic symptoms. The primary outcome measure was the change in a validated symptom severity scale from baseline to week 12. The study examined the difference in relief compared to placebo at an early time point in the study period.

Safety and Tolerability Findings

The safety analysis included all participants across both Phase 3 trials (n=2,150).

• Common Adverse Events: The most frequently reported events were mild to moderate gastrointestinal upset and headache.
• Neurological Effects: The studies noted the potential for side effects, such as drowsiness, which may affect driving capability. Participants reporting severe fatigue were monitored for dose-related effects.

---

Future Research Direction

These findings are part of the evidence base for the population and symptoms studied. Research is underway to explore the long-term safety profile of the compound in specialized patient populations over a two-year period. Ongoing studies are also investigating whether different dose titration schedules alter the incidence of common adverse events.

Key Studies & References

1. Serotonin–norepinephrine–dopamine reuptake inhibitor: Mechanism of action, pharmacokinetics, and clinical applications (Supporting the 'Pharmacological Activity' section)
2. Selective serotonin reuptake inhibitors (SSRIs): How they work, side effects, and uses (Supporting the adverse event profile and mechanism discussion)
3. VIGOR Trial (EORTC-2427) Protocol: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2/3 Astrocytoma (Providing the template for large-scale Phase 3 RCT design and safety monitoring)

Common questions about Vigor (FAQ)

Q: How long can a person expect Vigor to take before it starts working?

Sildenafil is known to be rapidly absorbed by the body. Official pharmacological studies indicate that in clinical settings, the onset of action has been observed in as little as 20 minutes.

Q: Are the side effects of Vigor temporary or do they continue with use?

Safety data from clinical trials generally describe adverse reactions associated with sildenafil as mild to moderate. These effects are often characterized as transient in nature, meaning they were typically short-lived or resolved over time in clinical trial settings.

Q: Does Vigor cause weight changes like weight gain or weight loss?

Regulatory safety documentation indicates that an increase in weight, fluid retention, and peripheral edema (swelling in the extremities) have been noted in some individuals taking sildenafil.

Q: How long does the body take to clear Vigor from its system?

The elimination half-life of sildenafil, which is the measure of how long it takes for the drug concentration to decrease by half, is typically reported to be approximately 3 to 4 hours.

Q: Is Vigor available as a generic medicine, and is it comparable to the brand name?

The active substance, sildenafil, is available in generic versions. Regulatory bodies assess these generic products to help ensure they meet quality standards and have dissolution profiles that are considered comparable to the original brand name product.

Q: Will Vigor interact with common foods or specific dietary supplements?

Official prescribing information explicitly states that consuming a high-fat meal may delay how quickly Vigor is absorbed into the body. Official documentation notes the importance of informing a healthcare provider about any herbal remedies, vitamins, or dietary supplements being taken.

Q: Is Vigor known to affect sleep patterns or cause insomnia?

Insomnia, or difficulty sleeping, is listed in official safety documents as a common adverse reaction associated with sildenafil use. Other neurological effects like abnormal dreams are also cited in some of the official safety data available.

Q: What should be done about common side effects like nausea or headaches from Vigor?

Regulatory guidance describes the importance of following the direction for use provided by the prescribing physician. If symptoms, including common side effects, become severe or concerning, official product information recommends contacting a physician.

Q: Is Vigor a type of steroid or antibiotic?

Vigor’s active ingredient, Sildenafil, is officially classified as a Phosphodiesterase type 5 (PDE5) Inhibitor. This class of medicine is known for its vasodilatory effect, meaning it helps to widen blood vessels, and it is not a steroid or antibiotic.

Q: Are there any required tests or monitoring while a person is taking Vigor?

Official documentation does not typically mandate specific routine bloodwork or tests during treatment. However, official documentation emphasizes that patients should ensure all medical staff, especially in emergency situations involving the heart, are aware that the medicine is being taken.

Q: What does the term 'contraindication' mean in relation to Vigor?

A contraindication is a strict regulatory term indicating that the use of the medication is prohibited under certain conditions, such as when taking specific other medicines like nitrates. This restriction is due to the potential for a high and serious risk of harm.

Q: Can Vigor cause changes in mood, like anxiety or depression?

Official safety documents list anxiety as a common adverse reaction associated with sildenafil use. Depression is also cited in some of the official safety data available for the compound.

Q: How effective was Vigor reported to be in clinical trials?

Studies supporting regulatory approval have shown statistically significant improvement in specific disease measures compared to placebo. For instance, the compound demonstrated improvement in the International Index of Erectile Function (IIEF) and the 6-minute walk distance test for Pulmonary Arterial Hypertension (PAH).

Q: Why do some people report feeling worse when they first start Vigor?

Sildenafil has vasodilatory properties which can lead to mild and temporary decreases in blood pressure. These effects may be experienced shortly after a dose, which can sometimes result in transient feelings of discomfort or feeling unwell.

Q: Is it acceptable to crush or split Vigor tablets if they are hard to swallow?

Vigor is supplied as a film-coated tablet intended for oral administration. Official instructions for the film-coated tablet do not specify methods for altering the tablet, such as crushing or splitting, before administration. An oral suspension formulation is available for specific populations.

Q: What is the usual duration of treatment with Vigor?

The duration of treatment depends on the condition being addressed. For continuous therapy, such as for Pulmonary Arterial Hypertension (PAH), extension studies have tracked patients receiving treatment for three years or longer, demonstrating sustained therapeutic benefit.

Q: How long has Vigor been approved and available for use?

The first regulatory authorization for the active substance sildenafil was granted by major authorities in 1998 for the Erectile Dysfunction (ED) indication. Later, an authorization was granted in 2005 for the Pulmonary Arterial Hypertension (PAH) indication.

Q: What is the reason Vigor is prescribed at such a low dose initially?

While specific dose reductions are required for certain populations (like older adults or those with organ impairment), in general, prescribing the lower end of the dose range is standard practice. This conservative approach is often used to assess a patient's tolerance to the medicine and limit the potential for early side effects.

Q: What are the reasons Vigor might be discontinued by a healthcare provider?

Discontinuation from clinical trials was noted to be higher in some dose groups and typically occurred due to adverse events, such as side effects. This is in addition to the strict regulatory criteria for contraindications that necessitate stopping the medication.

️ How to Store and Dispose of Vigor

---

Storage Guidelines

Store Vigor (sildenafil citrate) at room temperature, specifically between 59°F and 86°F (15°C and 30°C). Keep the medication in its original container, tightly closed, and away from moisture and excessive heat. Do not store it in the bathroom. Ensure the drug is kept out of the reach of children and pets.

---

Disposal Instructions

Do not flush Vigor down the toilet or pour it into a drain unless specifically instructed to do so. The best way to dispose of expired or no longer needed medication is through a drug take-back program. Consult your pharmacist or local waste disposal company for information about programs in your community. If a take-back program is unavailable, mix the medication with an undesirable substance, like kitty litter or used coffee grounds, place it in a sealed bag or container, and discard it in the household trash.